Search
News
Adient Q3 FY2026 Earnings: Adjusted EBITDA Holds Flat Despite $32 Million in Headwinds
Adient (NYSE: ADNT) reported fiscal Q3 2026 GAAP net income of $25 million, diluted EPS of $0.32 and adjusted diluted EPS of $0.48. Adjusted EBITDA was $225 million, essentially flat year over year, even as the Middle East conflict and customer- and supplier-driven inefficiencies created about $32 million of temporary headwinds. Free cash flow supported $30 million of quarterly share repurchases. At June 30, cash was $924 million and net debt was about $1.5 billion. The abbreviated release did not disclose revenue or free cash flow dollars.
TradingKey
Wed, Aug 5
Flutter Q2 2026 earnings: Revenue rose 3% as margins contracted
Flutter Entertainment’s fiscal Q2 2026 revenue increased 3% to $4.326 billion, while diluted EPS swung to a $1.57 loss from $0.59 earnings. Adjusted EBITDA fell 45% to $508 million as US sportsbook revenue weakened, UK gaming taxes rose and FIFA World Cup marketing increased. US revenue declined 6%, while International revenue grew 10%. Operating cash flow was nearly flat at $363 million, and Flutter lowered its 2026 group revenue and adjusted EBITDA midpoints to $17.91 billion and $2.655 billion, respectively.
TradingKey
Wed, Aug 5
Hagerty Q2 2026 Earnings: Premium Growth Was Masked by the Markel Transition
Hagerty’s Q2 2026 revenue fell 6.5% to $354.8 million and diluted EPS moved to a $0.02 loss from $0.09, as the Markel fronting transition eliminated commission revenue and added $64.1 million of pretax transitional costs. Written premium rose 19.2% to $424.5 million, earned premium climbed 41.7% to $252.0 million, and adjusted EBITDA increased 2.6% to $74.5 million. Hagerty also raised its 2026 outlook, including adjusted EBITDA guidance of $270 million to $280 million, while first-half operating cash flow reached $186.2 million.
TradingKey
Wed, Aug 5
Eos Q2 2026 Earnings: Revenue Jumps but Losses Remain Elevated
Eos Energy Enterprises reported Q2 2026 revenue of $68.8 million, up 351% year over year, while its gross margin improved to negative 71% from negative 203%. The company still posted a $275.7 million net loss attributable to shareholders and a $71.4 million adjusted EBITDA loss. One FPUSA-related project generated about 80% of quarterly revenue, highlighting concentration even as backlog reached $807 million. Eos narrowed full-year revenue guidance to $300 million-$350 million as it evaluates consolidating manufacturing at Thorn Hill.
TradingKey
Wed, Aug 5
Uber Q2 2026 Earnings: Bookings Growth Outpaces Revenue
Uber’s Q2 2026 revenue rose 12% to $14.2 billion, while Gross Bookings increased 24% to $58.0 billion and non-GAAP EPS advanced 35% to $0.81. Business model changes reduced reported revenue growth by eight percentage points, but non-GAAP operating income climbed 40% and free cash flow reached $2.8 billion. Mobility and Delivery both expanded segment profit, while GAAP net income benefited from a $1.6 billion pre-tax gain on equity investment revaluations. Q3 guidance calls for 18% to 22% constant-currency Gross Bookings growth.
TradingKey
Wed, Aug 5
Materion Q2 2026 earnings: Value-added sales rise 15% as EBITDA margin reaches 23.3%
Materion’s Q2 2026 net sales rose about 42% year over year to $613.9 million, while diluted EPS increased to $1.84 from $1.21. Value-added sales, which exclude pass-through metal costs, grew 15% to $308.2 million, and adjusted EBITDA reached $71.8 million with a 23.3% margin on value-added sales. The company generated $59 million in quarterly free cash flow and raised full-year adjusted EPS guidance to $6.80–$7.20, supported by stronger order momentum and a record backlog. All three operating segments delivered double-digit value-added sales growth.
TradingKey
Wed, Aug 5
Lilly Q2 2026 Earnings: Mounjaro and Zepbound Drive 48% Revenue Growth
Lilly’s Q2 2026 revenue rose 48% to $23.0 billion as Mounjaro and Zepbound demand drove a 60% volume increase, partly offset by a 13% decline in realized prices. GAAP diluted EPS increased 26% to $7.94 despite $3.03 per share of acquired IPR&D charges. Gross margin expanded 1.5 percentage points to 85.8% as production costs and product mix improved. Lilly raised full-year revenue guidance to $85-$87 billion and performance-margin guidance to 49.0%-50.5%, while narrowing non-GAAP EPS guidance to $35.50-$36.50.
TradingKey
Wed, Aug 5
Recursion Q2 2026 earnings: Expense cuts narrow the net loss
Recursion’s Q2 2026 revenue fell to $7.7 million from $19.2 million as Roche and Genentech revenue declined following completion of certain project phases. GAAP diluted loss per share improved to $0.25 from $0.41, and net loss narrowed to $131.0 million from $171.9 million as R&D and G&A expenses decreased. Quarterly operating cash use rose to $105.9 million, while cash, cash equivalents and restricted cash ended June at $556.8 million. Recursion lowered its 2026 cash operating expense ceiling to below $375 million and maintained cash runway guidance into early 2028.
TradingKey
Wed, Aug 5
FTC Solar Q2 2026 earnings: Revenue grows 31% but losses persist
FTC Solar’s Q2 2026 revenue rose 30.8% year over year to $26.2 million, while GAAP diluted loss widened to $1.69 per share from $1.18. GAAP gross margin improved to negative 8.5% from negative 19.6%, and adjusted EBITDA loss narrowed to $9.8 million. Product sales drove growth, contracted and awarded backlog was approximately $560 million, and management reiterated 40% full-year revenue growth. However, negative gross margin, a $27.1 million GAAP net loss and lower cash remain central concerns.
TradingKey
Wed, Aug 5
Freshpet Q2 2026 earnings: Volume growth supports higher guidance
Freshpet’s second-quarter 2026 net sales rose 15.5% to $305.6 million, driven by 15.7% volume growth, while diluted EPS increased to $0.39 from $0.33. GAAP gross margin expanded 120 basis points to 42.1%, and adjusted EBITDA grew to $52.2 million from $44.4 million. Lower input costs and better plant leverage supported profitability, though logistics expense and variable compensation raised SG&A as a percentage of sales. Freshpet also increased its 2026 sales growth and adjusted EBITDA guidance while maintaining its positive free cash flow target.
TradingKey
Wed, Aug 5
Bloomin’ Brands Q2 2026 Earnings: Margin Expansion Supports Higher EPS Guidance
Bloomin’ Brands reported Q2 2026 revenue of $1.016 billion, up 1.3% year over year, while diluted EPS from continuing operations increased to $0.37 from $0.29 and adjusted EPS reached $0.39. Restaurant-level operating margin expanded 40 basis points to 12.4%, supported by pricing, productivity initiatives, and lower pre-opening and health insurance costs, partly offset by inflation and advertising. The company raised full-year GAAP and adjusted EPS guidance, narrowed its U.S. comparable-sales range, and guided to an adjusted loss for Q3.
TradingKey
Wed, Aug 5
Utz Q2 2026 earnings: Adjusted margins rise despite a GAAP loss
Utz Brands’ fiscal Q2 2026 net sales rose 1.4% to $371.8 million, while reported diluted EPS fell to $(0.11) from $0.12 and adjusted EPS increased 11.8% to $0.19. Branded Salty Snacks organic sales grew 3.3%, but lower volume/mix and a 12.1% decline in Non-Branded & Non-Salty Snacks limited overall growth. Adjusted gross margin expanded 150 basis points and adjusted EBITDA rose 14.4% to $55.7 million, although GAAP net income swung to a $16.0 million loss.
TradingKey
Wed, Aug 5
NiSource Q2 2026 earnings: Profit declines but guidance remains unchanged
NiSource’s Q2 2026 GAAP net income available to common shareholders fell to $45.5 million from $102.2 million, while diluted EPS declined to $0.09 from $0.22. Adjusted EPS was $0.16, down from $0.22, as weather versus normal, NIPSCO work-continuity costs and Value Captured initiative expenses affected reported results. Six-month adjusted EPS still rose to $1.22 from $1.19. NiSource reaffirmed 2026 consolidated adjusted EPS guidance of $2.02-$2.07 and its 9%-10% adjusted EPS CAGR target through 2033, backed by a $28.6 billion capital plan.
TradingKey
Wed, Aug 5
NCR Voyix Q2 2026 earnings show recurring growth behind the hardware transition
NCR Voyix reported Q2 2026 revenue of $523 million, down 21% year over year as its Hardware Business Transition changed revenue recognition, but up 1% on a pro forma comparable basis. Recurring revenue rose to $435 million, adjusted EBITDA increased to $98 million from $93 million, and non-GAAP diluted EPS held at $0.17. The company maintained its full-year 2026 outlook, including adjusted EBITDA of $432 million to $447 million and adjusted free cash flow-unrestricted before restructuring of $190 million to $220 million.
TradingKey
Wed, Aug 5
Compass Pathways Q2 2026 earnings: Warrant revaluation drives wider net loss
Compass Pathways’ Q2 2026 results showed a net loss of $253.8 million, or $1.88 per share, versus $38.4 million and $0.41 a year earlier. A $205.6 million non-cash warrant fair-value loss drove most of the increase, while operating expenses rose approximately 22% as commercial-readiness spending expanded. Cash and cash equivalents ended the quarter at $433.3 million, which management expects to fund operations and capital spending into 2028. The rolling COMP360 NDA remains targeted for completion in Q4 2026.
TradingKey
Wed, Aug 5
Delek US Q2 2026 Earnings: Refining Margins Drive a Return to Profit
Delek US reported second-quarter 2026 net revenue of $4.087 billion, up 47.8% year over year, and diluted EPS of $2.71 versus a $1.76 loss. Adjusted EBITDA rose to $638.7 million from $177.9 million as higher crack spreads lifted refining results, although excluding the RVO adjustment it was $490.1 million. Refining adjusted EBITDA reached $566.2 million, logistics delivered a record $143.5 million, and operating cash flow increased to $262.9 million despite a $137.9 million unfavorable working-capital impact. The quarter ended with $628.6 million in cash.TradingKey
Wed, Aug 5
United Therapeutics Q2 2026 earnings: Lower taxes lift EPS as revenue slips
United Therapeutics (UTHR) reported Q2 2026 revenue of $783.3 million, down 2% year over year, while net income rose 8% to $333.0 million and diluted EPS increased 13% to $7.27. Total Tyvaso sales declined 4% as an 18% drop in Nebulized Tyvaso outweighed 4% growth in Tyvaso DPI. Operating income fell 9% and calculated gross margin narrowed, but an 11% effective tax rate and a lower diluted share count supported earnings growth. Higher R&D and inventory reserve costs remained important operating pressures.
TradingKey
Wed, Aug 5
Cencora Fiscal Q3 2026 Earnings: OneOncology Supports Margin Expansion
Cencora’s fiscal Q3 2026 revenue rose 5.1% to $84.8 billion, while GAAP diluted EPS increased 11.9% to $3.94 and adjusted EPS advanced 12.0% to $4.48. The OneOncology acquisition supported a 66-basis-point increase in GAAP gross margin and stronger U.S. Healthcare Solutions profit, although acquisition-related expenses and financing pushed net interest expense higher. Cencora repurchased $1 billion of shares and raised fiscal 2026 adjusted EPS guidance to $17.75-$17.95. International revenue and operating income also grew, led by European distribution and global specialty logistics.
TradingKey
Wed, Aug 5
Kennametal Fiscal Q4 2026 Earnings: Raw-Material Pricing Lifts EPS to $2.91
Kennametal’s (NYSE: KMT) fiscal Q4 2026 revenue rose 43% to $736.6 million, with organic growth of 42%, while diluted EPS climbed to $2.91 from $0.28. GAAP operating margin reached 41.1%, largely reflecting a $252 million favorable timing gap between raw-material pricing and costs. Infrastructure led segment growth, but full-year operating cash flow fell to negative $4.0 million as higher tungsten prices, inventory and supplier prepayments absorbed cash. The company issued fiscal 2027 sales guidance of $3.33 billion to $3.45 billion and adjusted EPS guidance of $4.15 to $5.15.
TradingKey
Wed, Aug 5
Dynatrace Q1 FY2027 Earnings: ARR Grows 17% as Cash Flow Rises
Dynatrace’s fiscal Q1 2027 revenue rose 16% year over year to $554.5 million, while ARR increased 17% to $2.136 billion. Non-GAAP diluted EPS improved to $0.48 from $0.42 and adjusted free cash flow climbed to $309.2 million, but GAAP diluted EPS fell to $0.12 as tax expense increased and non-operating income declined. The company lowered its reported-dollar full-year ARR and revenue ranges mainly because of foreign exchange changes, while retaining its constant-currency ARR growth outlook and modestly raising the midpoint of constant-currency revenue growth.
TradingKey
Wed, Aug 5
Featured Tools
Top News
Oracle Stock Forecast: $630 Billion AI Order Backlog Awaits Revaluation, Can the Stock Continue to Recover?
New CEO Ternus Launches iPhone 18 Pro on September 9 — Can Apple Reverse Q3 China Miss Before Jackson Hole?
Micron vs. SK Hynix: As HBM Demand Continues to Surge, Which Memory Stock Deserves More Attention?
Western Digital Shares Plunge 50%: Is It the Best Time to Buy?
Cerebras Cloud Revenue Nearly Quadrupled — But Why Did the Stock Crash 17% on "Confusing" GAAP Results?
